BCL2 and B-cell chronic lymphocytic leukemia: Western blot analyses showed that in vivo ibrutinib treatment decreased Bcl-2 expressions in CLL B-cells from most of the patients (n=7) tested and Mcl-1 expressions in P2, P8 and P12 but had no effect on XIAP expressions in these patients (Figure 3C).